CSOP Hang Seng Biotech ETF (03174.HK) up 4.79% intraday on policy catalysts

NewTimeSpace News: Hong Kong's pharmaceutical and biotech sector rallied broadly on Monday morning, As of 10:23 HKT on September 21, 2026, CSOP Hang Seng Biotech ETF (03174.HK) rose 4.79% intraday to HK$3.938, with turnover of HK$1.7806 million.

NewTimeSpace learned that the ETF, managed by CSOP Asset Management, tracks the Hang Seng Biotech Index and focuses on Hong Kong-listed biotech and innovative drug leaders, with major holdings including WuXi Biologics, Innovent Biologics, BeiGene, WuXi AppTec, CSPC Pharmaceutical and GenScript Biotech.

On the news front, on September 18, ten government departments led by the Ministry of Industry and Information Technology jointly issued the 15th Five-Year Plan for the development of the pharmaceutical industry, targeting no less than RMB3.5 trillion in revenue of above-scale drug makers by 2030 and no less than 20% annual growth for the innovative drug industry; on September 20, the National Medical Products Administration said it would advance the drug experimental data protection system and establish market exclusivity periods for pediatric and rare-disease drugs, lifting risk appetite across the sector.

Industrial Securities noted that innovation and globalization remain the core themes of the pharma sector, with the global competitiveness of Chinese innovative drugs continuing to strengthen and policy support and commercialization logic intact. 

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.